Recent Updates
Recently added Catalysts

Atrium Therapeutics, Inc.

RNAFDA catalysts, PDUFA dates & pipeline intelligence
$8.19
▼ -0.01 · -0.12%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full RNA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $7.4952W HIGH $73.06
Volume
83.28 K
Value Traded
1.34 M
Short % Float
15.71%
Days to Cover
8.3
+6.37%Week
-3.86%1 Month
-30.03%3 Month
-37.25%6 Month
-10.22%5 Year
-10.22%All Time

Cash Data

Unlock RNA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
139.58 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-125.34 M
Total Shares
17.11 M
Float Shares
21.62 M
Insiders
2.96%
Institutions
63.87%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
IND Submission
ATR 1072
PRKAG2 syndrome
INDRNA-Based TherapiesRare Diseases
Unlock every RNA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

RNA Catalyst Timeline

Dated clinical, regulatory and corporate events for Atrium Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Atrium Therapeutics, Inc.

530Total events
20Upcoming
97Tier-1 (high impact)
2019 to 2028Coverage

Upcoming catalysts 2

T2First Patient Dosed
Subscribe to view catalyst details
T3Enrollment Milestone
Subscribe to view catalyst details

Event history 50

◆Timing GuidancePresentation
Private placement expected to close
source ↗
▼Equity OfferingCorporate
$50 million private placement priced at-the-market
source ↗
▲IND ClearanceIND
FDA clearance of IND for ATR 1072
PRKAG2 syndromesource ↗
▲Other Regulator MilestoneEx-US Regulatory
Health Canada No Objection Letter for ATR 1072
PRKAG2 syndromesource ↗
▲Trial InitiationTrial
Initiated clinical site activities for Corventis
PRKAG2 syndromesource ↗
●Quarterly UpdateCorporate
Q2 2026 financial results reported
source ↗
▲Milestone PaymentCorporate
Second milestone payment from Bristol Myers Squibb
source ↗
▲Milestone PaymentCorporate
Second milestone payment from Bristol Myers Squibb
source ↗
●Quarterly UpdateCorporate
Second quarter 2026 financial results reported
source ↗
▲IND ClearanceIND
FDA clearance of IND for ATR 1072
PRKAG2 syndromesource ↗
Unlock the full RNA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How RNA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
-Example Drug Phase 3 data readout Phase 3
Unlock all RNA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 79%
Micro Cap
(rank 519 of 657)
Percentile Rank
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
ATR 1072 Small moleculeNCT07738107Cardiac GlycogenosisPhase 1 RECRUITING 37Oct 1, 2028
Unlock the RNA pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every RNA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Del-zota
BreakthroughFast TrackOrphan+1
Duchenne muscular dystrophy (DMD)2026-02-26Near Normalization of CK LevelsRead MoreAvidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceRead More
Scroll for more · summaries link to the source press release
Unlock every RNA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock RNA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Kenney StephanieOfficer (See Remarks)Grant/Award 30,000 35,460 held$0.00 04/20/2026
Unlock the full RNA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in RNA

Fund % of Portfolio Current MV Shares Owned Activity
DAFNA Capital Management LLC 0.3 % 1.72 M 128.00 K
Unlock every fund holding RNA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in RNA
Shares held by hedge funds each quarter, and who bought or sold.

RNA Institutional Ownership Trends

RNA Short Interest

Shares sold short, counted twice a month.

15.71%
Short % of Float
of tradable shares sold short
3.4M
Shares Sold Short
-0.1% vs prior count
8.3 High
Days to Cover
trading days of normal volume to buy every short share back
410.9K
Avg Daily Volume
the average used for days to cover
Unlock RNA short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-12-18
Unlock RNA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live RNA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock RNA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How RNA ranks across every disease it competes in

Competitive Position is a premium feature
See how RNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

RNA News

RNA
Oct 20, 2026
RNAGeneral

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics announced inducement grants for a newly hired employee under its 2026 Employment Inducement Incentive Award Plan. The grants include stock options and restricted stock units, approved by the Board's Human Capital Management Committee. The company is also advancing its first precision cardiology program, ATR 1072, into clinical trials.

Read more →
RNA
Oct 8, 2026
RNAGeneral

Atrium Therapeutics Announces $50 Million Private Placement

Atrium Therapeutics has announced a $50 million private placement to fund its RNA therapeutics aimed at cardiomyopathies. The financing involves issuing shares and pre-funded warrants, with participation from several institutional investors. The company plans to use the proceeds for product development and operational costs, ensuring funding through 2028.

Read more →
RNA
Sep 2, 2026
RNAConferences/Events

Atrium Therapeutics to Participate in Upcoming Investor Conferences

Atrium Therapeutics, Inc. announced its participation in several upcoming investor conferences in September 2026. The company has made significant advancements, including FDA clearance for its IND application for ATR-1072, aimed at treating PRKAG2 syndrome. Additionally, Atrium is launching a Phase 1/2 clinical trial and has reported its second quarter financial results.

Read more →
RNA
Aug 20, 2026
RNAGeneral

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics has announced the awarding of inducement grants to a newly hired employee under its 2026 Employment Inducement Incentive Award Plan. The grants include non-qualified stock options and restricted stock units, approved by the company's Board of Directors. Additionally, Atrium is progressing its precision cardiology program into clinical trials following FDA clearance for its IND application for ATR 1072.

Read more →
RNA
Aug 13, 2026
RNAPhases

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

Atrium Therapeutics reported positive financial results for Q2 2026, highlighting FDA clearance for ATR 1072 and the launch of the Corventis Phase 1/2 trial for PRKAG2 syndrome. The company also achieved a $15 million milestone payment from Bristol Myers Squibb. Atrium aims to enroll the first participant in the trial by the end of 2026, with initial data expected in 2027.

Read more →
RNA
Aug 13, 2026
RNAGeneral

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Atrium Therapeutics has secured a $15 million milestone payment from Bristol Myers Squibb for the successful delivery of a lead compound in their cardiovascular collaboration. This payment is part of a broader agreement that could yield up to $1.35 billion in milestone payments. Atrium is advancing its RNA therapeutics aimed at treating serious heart diseases, including rare genetic cardiomyopathies.

Read more →
RNA
Jul 14, 2026
RNAFDA Updates

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Atrium Therapeutics has received FDA clearance for its Investigational New Drug application for ATR 1072, aimed at treating PRKAG2 syndrome. The Corventis™ Phase 1/2 trial will assess the safety and efficacy of ATR 1072, which utilizes RNA technology to address the underlying genetic causes of the disease. The trial is expected to enroll its first participant by the end of 2026, with initial data anticipated in 2027.

Read more →
RNA
May 14, 2026
RNAGeneral

Atrium Therapeutics Reports First Quarter 2026 Financial Results

Atrium Therapeutics reported its Q1 2026 financial results, showcasing a strong start as an independent company. The firm highlighted a successful collaboration with Bristol Myers Squibb, earning a $15 million milestone payment. Atrium is advancing its lead programs, ATR 1072 and ATR 1086, towards clinical trials, supported by a robust cash position of $267.8 million.

Read more →
RNA
Apr 21, 2026
RNAGeneral
▼ -5.4%on this newsshared move

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 20, 2026

Atrium Therapeutics announced the award of inducement grants to seven newly hired non-executive employees under its 2026 Employment Inducement Incentive Award Plan. The grants include non-qualified stock options for 101,250 shares and restricted stock units for 50,625 shares, aimed at incentivizing new talent. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to enhancing its workforce.

Read more →

About Atrium Therapeutics, Inc.

San Diego, CA 391 employees aviditybiosciences.com
Headquarters3020 CALLAN ROAD, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next RNA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime